Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

Homologous recombination repair gene mutations (HRRm) are common in urothelial carcinoma (UC), rendering tumor cells sensitive to poly (ADP-ribose) polymerase (PARP) inhibition. We assessed efficacy and safety of durvalumab (anti–programmed cell death ligand-1) plus olaparib (PARP inhibitor) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Jonathan E., Park, Se Hoon, Kozlov, Vadim, Dao, Tu V., Castellano, Daniel, Li, Jian-Ri, Mukherjee, Som D., Howells, Kathryn, Dry, Hannah, Lanasa, Mark C., Stewart, Ross, Bajorin, Dean F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788981/
https://www.ncbi.nlm.nih.gov/pubmed/35737919
http://dx.doi.org/10.1200/JCO.22.00205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788981/
https://www.ncbi.nlm.nih.gov/pubmed/35737919
http://dx.doi.org/10.1200/JCO.22.00205

Ejemplares similares